Clinical Trials

138 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

798 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT07291076 2026-06-02

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

198 enrolled

Carcinoma, Hepatocellular

NCT04751370 2026-05-29

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

31 enrolled

Rectal Neoplasms

NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

143 enrolled 16 charts

GastrointestinalGenitourinaryHead & NeckThoracic

Anal Canal Carcinoma, Anus Neoplasms

NCT05176483 2026-05-27

STELLAR-002

Phase 1 Recruiting

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07587827 2026-05-14

ODI-2001-01

Phase 1 Not yet recruiting

77 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

74 enrolled

Phase 1 Not yet recruiting

Pancreatic Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT06941857 2026-05-05

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2 Recruiting

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

226 enrolled

Carcinoma, Hepatocellular

NCT07563738 2026-05-04

TEADCO

GastrointestinalOther solid neoplasmThoracic

229 enrolled

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT04472767 2026-04-30

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Phase 2 Recruiting

35 enrolled

Carcinoma, Hepatocellular

NCT07075120 2026-04-30

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Phase 1 Recruiting

15 enrolled

Carcinoma, Hepatocellular

NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Completed

17 enrolled 8 charts

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled